Table 1

Baseline patient characteristics (n = 78)

Age (years), median (IQR)

56.4 (48 to 66.75)


Body Mass Index (kg/m2), median (IQR)

26.6 (24.4 to 30.2)


Female

61 (78.2%)


Ever Smoked

47 (60.3%)


Current smokers

22 (28.2%)


Caucasian race

73 (93.6%)


*Continuing triple DMARD therapy

51 (65.4%)


*Continuing methotrexate

60 (76.9%)


*Continuing sulfasalazine

60 (76.9%)


*Continuing hydroxychloroquine

70 (89.7%)


Initiation of leflunomide with loading dose

7 (9.0%)


Anti-CCP antibody (n = 77)

38 (49.4%)


Rheumatoid factor

46 (59.0%)


Shared epitope (n = 76)

52 (68.4%)


Duration of disease prior to initiation of leflunomide (weeks), median (IQR)

48 (32.3 to 92.1)


DAS28 (at start of leflunomide therapy), median (IQR)

5.8 (5.2 to 6.5)


*- Participants could be included in any or all of these groups.

Wiese et al. Arthritis Research & Therapy 2012 14:R163   doi:10.1186/ar3911

Open Data